Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
The Company reports the following operating highlights for the third quarter:
•The U.S. Food and Drug Administration (FDA) granted orphan drug status to the Company’s HART-Trachea product, which is intended to replace or repair a trachea that has been severely damaged by either physical trauma or cancer.
Help employers find you! Check out all the jobs and post your resume.
